CTi Biopharma

CTIC NASDAQ
0.8851
+0.0173
+1.99%
Closed 16:39 05/21 EDT
Open
0.9200
Prev Close
0.8678
High
0.9283
Low
0.8401
Volume
139.97K
Avg Vol (3M)
271.31K
52 Week High
5.36
52 Week Low
0.6001
% Turnover
0.24%
Market Cap
51.32M
1D
5D
1M
3M
1Y
5Y

Comments

No Data

Related

Webull offers CTi Biopharma CTIC stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
MORE >

Recently

Name
Price
%Change